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Summary
 
Mast cells (MCs) arise in situ from circulating stem cell factor (SCF)-dependent committed
progenitors (PrMCs) and accumulate at sites of allergic mucosal inflammation. We hypothesized
that human (h)PrMCs and their mature counterparts might share overlapping patterns of chemo-
kine and cytokine receptor utilization with eosinophils, basophils, and T helper type 2 (Th2)
lymphocytes for their homing and allergy-associated hyperplasia. We have characterized com-
mitted hPrMCs and fully mature hMCs derived in vitro from cord blood for their functional
responses to chemokine and cytokine agonists germane to allergic inflammation and for their
maturation-related expression of the corresponding receptors. After 4 wk of culture in the
presence of recombinant stem cell factor (SCF), interleukin (IL)-6, and IL-10, the cells were
characterized as hPrMCs based upon their uniform surface expression of c-
 
kit
 
 and CD13, low-
level expression of Fc
 
e
 
RI
 
a
 
, absence of CD14 and CD16 expression, and immunoreactivity for
MC chymase in 
 
.
 
80%, and about half were immunoreactive for tryptase and metachromatic
with toluidine blue. By week 9, the cells had matured into hMCs, identified by higher levels of
c-
 
kit
 
, continued expression of CD13 and low-level Fc
 
e
 
RI
 
a
 
, uniform toluidine blue metachro-
masia, and uniform immunoreactivity for both tryptase and chymase. The 4-wk-old hPrMCs
expressed four chemokine receptors (CXCR2, CCR3, CXCR4, and CCR5). Each receptor
mediated transient rapid calcium fluxes in response to its respective ligand. Both recombinant
human eotaxin and stromal cell–derived factor 1
 
a
 
 elicited chemotaxis of hPrMCs. Only
CCR3 was retained on the mature 9-wk-old hMCs from among these chemokine receptors,
and hMCs responded to eotaxin with a sustained calcium flux but without chemotaxis. The
Th2 cytokines IL-3, IL-5, IL-6, IL-9, and granulocyte/macrophage colony-stimulating factor
each augmented the SCF-dependent proliferation of hPrMCs and hMCs. In contrast, the pro-
totypical Th1 cytokine, interferon 
 
g
 
, suppressed SCF-driven proliferation of both hPrMCs and
hMCs. Thus, throughout their development in vitro, hMCs obey SCF-dependent, cytokine-
driven mitogenic responses that reflect a Th2-type polarization characteristic of allergy and
asthma. Furthermore, committed hPrMCs have a unique profile of chemokine receptor ex-
pression from among reported hematopoietic cells, including CCR3, which is shared with the
other cells central to allergic inflammation (eosinophils, basophils, and Th2 lymphocytes).
Key words: chemokines • asthma • HIV • calcium ﬂux • stem cell factor
 
M
 
ast cells (MCs)
 
1
 
 are ubiquitously distributed to mu-
cosal and cutaneous surfaces, as well as to microvascu-
lar sites in connective tissues. This distribution facilitates their
role in adaptive immune responses to intestinal helminthic
parasites and in innate host resistance to gram-negative bac-
 
terial infections in experimental models (1, 2). In humans,
MCs activated by IgE-dependent or idiosyncratic mech-
anisms  release potent bioactive inflammatory mediators
with direct pathobiologic roles in asthma, rhinitis, urticaria,
and anaphylaxis (3–7). Tissue MCs differentiate and mature
in situ from committed progenitor cells (PrMCs), which
arise in the marrow compartment from pluripotent he-
matopoietic progenitors (8, 9) and circulate as mononu-
clear leukocytes lacking characteristic secretory granules
 
1
 
Abbreviations used in this paper:
 
 ETX, eotaxin; MCs, mast cells; MCP,
monocyte chemotactic proteins; MIP, macrophage inflammatory protein;
Pr, progenitor; RANTES, regulated on activation, normal T cell ex-
pressed and secreted; RT, reverse transcriptase; SCF, stem cell factor;
SDF, stromal cell–derived factor; SSC, side angle light scatter. 
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(10, 11). Circulating PrMCs differ from monocytes by
their surface expression of the receptor for stem cell factor
(SCF), c-
 
kit
 
 (10), by their SCF-dependent proliferation in
vitro that is strongly augmented by IL-3 in both humans
(12) and mice (11), and by their lack of CD14 expression
(13). The normal development of all tissue MC populations
in vivo requires SCF, which is constitutively produced by
stromal cells. Additional factors that are derived from T
lymphocytes, including IL-3 (14), are required for the de-
velopment of the MC subpopulation that normally resides
in the intestinal epithelium in both mice and humans but
not for MC development in the skin or connective tissues.
Intraepithelial MCs are depleted in the absence of T lym-
phocytes (15, 16). Conversely, their numbers increase in in-
testinal helminthic infections in mice (14) and in bronchial
wall inflammation in humans with asthma (17–19). The
regulation of tissue localization, proliferation, and viability
of hPrMCs, as well as their terminal differentiation into
hMCs, must include constitutive mechanisms that ensure
normal numbers of tissue hMCs within connective tissues
and inducible mechanisms that maintain and/or increase
the supply of hPrMCs within intraepithelial compartments
for T cell–dependent reactive hMC responses.
The hyperplasia of mucosal MCs, both in human asthma
and in helminthic infections in mice, occurs concomitantly
with local recruitment and activation of T lymphocytes
bearing the T helper type 2 (Th2) phenotype, with atten-
dant local production of IL-3, IL-4, IL-5, IL-6, IL-9, IL-
13, GM-CSF, and other cytokines, and with a tissue eosi-
nophilia (20). Cytokines, derived from Th2 cells orches-
trate several aspects of allergic inflammation and emanate
from a genetic locus on the long arm of chromosome 5,
containing several genes with candidate roles in asthma and
allergic disease (21, 22). IL-3, GM-CSF, and IL-5 are im-
plicated in tissue eosinophilia, as each supports eosinophil
development (23), sustains eosinophil viability (24), and
converts mature eosinophils from a resting phenotype to a
functionally primed state (25). Composite data from ani-
mal models of allergic inflammation indicate that these cy-
toprotective cytokines, particularly IL-5, act cooperatively
with chemoattractive cytokines (chemokines) to orches-
trate tissue eosinophilia (26, 27). Several CC chemokines
induce the directed migration of eosinophils from the pe-
ripheral blood and produce their activated adhesion, both
of which are necessary for net cell accumulation (28). Of
the eosinophil-active chemokines, eotaxin (ETX) is partic-
ularly implicated in the mucosal inflammation of allergic
diseases, being expressed by epithelial and endothelial cells
at sites of allergic inflammation (29). Increases in lung
ETX levels accompany bronchial eosinophilia in humans
with asthma (30) and are elicited by allergen challenge by a
T cell–dependent mechanism in experimental models (31).
The recent additional demonstration of the ETX receptor
(CCR3) (32) on human peripheral blood basophils (33) and
human Th2 lymphocytes (34) suggests that ETX may par-
ticularly recruit several blood-borne cells that participate in
allergic inflammation. Completion of the cellular profile of
allergic tissue inflammation would likely include both
chemokine-induced attraction and Th2 cytokine–mediated
hyperplasia of SCF-dependent PrMCs.
Although hMCs were previously developed from cultures
of bone marrow cells (9), fetal liver cells (35), and cord
blood mononuclear cells (36) using SCF with or without
IL-6, there has been no definition of the membrane pheno-
type of the hPrMCs or hMCs derived in vitro with regard
to cytokine and chemokine receptor expression. Further-
more, although IL-3, IL-4, IL-5, and IL-6 were each cyto-
protective for hMCs (37), the potential role for these and
other Th2 cytokines as mitogens or comitogens with SCF
has not been characterized during developmental progres-
sion of hMCs. Given that reactive MC hyperplasia is a fre-
quent concomitant of Th2-polarized immune responses, we
hypothesized that MC might obey overlapping patterns of
chemokine and cytokine receptor utilization with eosino-
phils, basophils, and Th2 lymphocytes. We recently reported
the development of homogeneously pure PrMCs (meta-
mastocytes) from uncommitted mouse bone marrow cells
using a triad of SCF, IL-6, and IL-10 (38). Using the anal-
ogous combination of recombinant human growth factors,
we now report the characterization of chemokine and cyto-
kine receptor utilization by hPrMCs derived in vitro from
cord blood and maturation-related alterations in these pa-
rameters during their differentiation into fully mature hMCs.
hPrMCs express CCR3, CXCR4 (the receptor for the
constitutively produced lymphocyte chemoattractant stro-
mal cell–derived factor [SDF]-1
 
a
 
) (39), CCR5 (the receptor
for the Th1-active chemokine macrophage inflammatory
protein (MIP)-1
 
a
 
) (40), and an IL-8 receptor, CXCR2 (28).
These receptors each mediate intracellular calcium flux in
hPrMCs in response to their respective ligands, and both
ETX and SDF-1
 
a
 
 promote chemotaxis in a dose-depen-
dent fashion. The presence of these receptors, along with
CD4, on hPrMCs could provide a previously unrecognized
cellular reservoir for HIV. Additionally, the SCF-driven
mitogenesis of both hPrMCs and their mature counterparts
is augmented by several members of the Th2 cytokine gene
cluster that are implicated as potential candidate genes in
human asthma (IL-3, IL-5, IL-6, IL-9, and GM-CSF),
whereas a Th1 cytokine, IFN-
 
g
 
, inhibits mitogenesis. The
expression of CXCR4 by hPrMCs during their lineage de-
velopment suggests that SDF-1
 
a
 
 may contribute to the stro-
mal distribution of hPrMC under basal conditions, whereas
the presence of both functional CCR3 and Th2 cytokine
responses provides a potentially critical link between T cell
activation, allergic inflammation, and the hyperplasia of in-
traepithelial MCs in human allergic disease.
 
Materials and Methods
 
Cytokines and Chemokines.
 
The recombinant human cyto-
kines SCF and IL-6 were provided by Amgen. Recombinant hu-
man IL-2, IL-3, IL-4, IL-5, IL-9, IL-10, IL-12, IL-13, IFN-
 
g
 
,
GM-CSF, granulocyte (G)-CSF, and macrophage (M)-CSF were
purchased from Endogen; and ETX, IL-8, MIP-1
 
a
 
, and SDF-1
 
a
 
were from PeproTech, Inc. 
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Culture of hPrMCs and hMCs.
 
hPrMCs were derived from
cord blood mononuclear cells cultured in the presence of SCF,
IL-6, and IL-10, as previously described for the development of
mouse PrMCs (38). Heparin-treated umbilical cord blood was
obtained from placentas after routine cesarean section deliveries.
After dextran sedimentation of the blood to remove erythrocytes,
the interfaces containing mononuclear cells were obtained by
centrifugation of the buffy coats through a cushion of Ficoll-
Hypaque
 
®
 
 (1.77 g/ml; Pharmacia). Residual erythrocytes were
removed by hypotonic lysis, and the mononuclear cells were sus-
pended in RPMI 1640 (GIBCO BRL) supplemented with 10%
fetal bovine serum (Sigma Chemical Co.), 2 mM 
 
l
 
-glutamine,
0.1 mM nonessential amino acids, 0.2 
 
m
 
M 2-ME, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, and 2 
 
m
 
g/ml gentamycin. The
cell suspensions were seeded at a density of 10
 
6
 
 cells/ml and cul-
tured in the presence of 100 ng/ml SCF, 50 ng/ml IL-6 (added
because of its synergistic effects for SCF-driven hMC develop-
ment from cord blood mononuclear cells; reference 36), and 10
ng/ml IL-10, which was included because of its synergistic effect
for mouse MC development with SCF and IL-3 (41, 42) and
because of its suppressive effect on endogenous production of
GM-CSF and resultant proliferation of granulocytes and mono-
cytes (43). Cultures were carried for up to 9 wk. The entire vol-
ume of cytokine-supplemented medium was replaced on a weekly
basis, and the adherent fraction of cells was discarded weekly by
the transfer of the nonadherent cells to fresh culture flasks. Every
week, aliquots of 2 
 
3
 
 10
 
4
 
 cultured cells were spun onto glass
slides in a cytocentrifuge (Cytospin
 
®
 
 2; Shandon) and stained with
toluidine blue (which elicits a metachromatic reaction only in the
granules of MCs and basophils) as previously described (38).
 
Immunocytochemistry.
 
Cytocentrifugation slides were prepared
as described above, air dried, and fixed in Carnoy’s fluid (60%
ethanol, 30% chloroform, and 10% glacial acetic acid) for 10 min
at room temperature. After being washed with PBS three to four
times, the slides were blocked with 2% chicken egg albumin
(Sigma Chemical Co.) for 30 min at room temperature and incu-
bated with a 1:200 dilution of a mouse anti–human IgG1 mAb
that detects both human 
 
a
 
 and 
 
b
 
 tryptases (Chemicon Interna-
tional, Inc.) (44) with an affinity-purified rabbit anti–human chy-
mase antibody (provided by Dr. N. Schechter, University of
Pennsylvania, Philadelphia, PA) (16) or irrelevant isotype-matched
mouse monoclonal or rabbit IgG antibodies. These antibody probes
were chosen because of their specificity as MC markers. Immu-
nocytochemical procedures were carried out as previously de-
scribed with alkaline phosphatase as the chromogenic reporter
(45). The cells exhibiting strong immunoreactivity as indicated
by a red staining reaction were expressed as a percentage of 300
cells counted on each slide.
 
Flow Cytometry.
 
Flow cytometric analysis was carried out as
previously described (46). All analyses were carried out in the
presence of cold HBSS containing 2% fetal bovine serum, 0.1%
human serum, and 0.01% sodium azide (FACS buffer). 10
 
5
 
 cells
were incubated with mouse anti–human mAbs specific for the
following epitopes known to be expressed by mature MCs: c-
 
kit
 
(the receptor for SCF, expressed by PrMCs, abundantly by MCs,
and to a lesser degree by basophils [47] and eosinophils [46], recog-
nized by SR-1, an IgG2a antibody provided by Dr. V. Broudy,
University of Washington, Seattle, WA) (48); Fc
 
e
 
RI
 
a
 
 (the 
 
a
 
 sub-
unit of the high-affinity IgE receptor expressed by MCs and ba-
sophils, recognized by 22E7, an IgG1 mAb provided by Dr. R.
Chizzonite, Hoffmann-LaRoche, Nutley, NJ) (49); CD13 (an
epitope homologous to the K1 membrane aminopeptidase that
distinguishes mouse MCs from basophils (50, 51), recognized by
 
an IgG1 from PharMingen); and 
 
b
 
3 integrin (a component of the
vitronectin receptor expressed by mature dispersed hMCs from
skin, lung, and uterus [52], as well as by macrophages and some
peripheral blood monocytes [53, 54], recognized by an IgG1 from
PharMingen); the 
 
a
 
 subunit of the IL-3 receptor (IL-3R
 
a
 
,
lacked by lung hMCs [55] but likely expressed by hPrMCs from
peripheral blood based on their synergistic response to IL-3 with
SCF [12], recognized by an IgG1 from PharMingen); CD4 (inter-
acts with CCR3, CCR5, and CXCR4 to facilitate HIV entry
[56, 57]; not known to be expressed by hPrMCs or hMCs, recog-
nized by an IgG1 from PharMingen); the 
 
a
 
 subunit of the IL-5 re-
ceptor (IL-5R
 
a
 
, recognized by an IgG
 
1
 
 from PharMingen); CD14
(a monocyte marker, recognized by an IgG2a from PharMingen);
and CD16 (a neutrophil marker, recognized by an IgG1 from
PharMingen). The cells were also stained with the following
mAbs against chemokine receptors having the indicated known
cell specificities (58): CCR1 (a receptor for MIP-1
 
a
 
, monocyte
chemotactic proteins [MCP]-3 and -4 and RANTES [regulated
on activation, normal T cell expressed and secreted], expressed by
eosinophils, monocytes, dendritic cells and activated T lympho-
cytes; IgG
 
1
 
; R & D Systems, Inc.); CCR2 (a receptor for MCP-1,
-2, -3, -4, and -5, expressed by basophils, monocytes, activated T
cells, dendritic cells, and NK cells; IgG1; R & D Systems, Inc.);
CCR3 (the receptor for ETX and MCP 2-4, expressed by eosino-
phils, basophils, and Th2, recognized by 7B11, an IgG2a provided
by the National Institutes of Health (NIH) AIDS Repository,
Bethesda, MD); CCR4 (a receptor for thymus- and activation-
regulated chemokine, expressed by activated T cells and dendritic
cells; IgG1 hybridoma supernatant [1G1] provided by Lijun Wu,
LeukoSite, Inc.); CCR5 (a receptor for MIP-1
 
a
 
, MIP-1
 
b
 
, and
RANTES, expressed by monocytes, activated T cells, dendritic
cells, and NK cells recognized by 2D7, an IgG2a from the NIH
AIDS Repository); CCR6 (a receptor for MIP-3
 
a
 
, expressed by
dendritic cells, recognized by an IgG1 hybridoma supernatant
[11A9]; provided by P. Ponath, LeukoSite, Inc.); CXCR1 (a re-
ceptor for IL-8 and GCP-2, expressed by neutrophils, mono-
cytes, basophils, a subset of T lymphocytes and recently reported
on the surface of the transformed MC leukemia line [HMC-1]
and dispersed skin hMCs (59), clone 5A12, IgG2b; PharMingen);
CXCR2 (a receptor for IL-8, granulocyte chemotactic protein 2,
growth-related oncogene, epithelial neutrophil-activating peptide,
neutrophil-activating peptide 2 and LPS-induced CXC chemo-
kine, with a distribution similar to CXCR1; clone 6C6, IgG1;
PharMingen); CXCR3 (receptor for IP-10, monokine induced
by IFN-
 
g
 
, and IFN-inducible T cell 
 
a
 
 attractant, expressed by
NK cells and Th1, recognized by an IgG1 hybridoma supernatant
[11A9]; provided by P. Ponath, LeukoSite, Inc.); and CXCR4
(receptor for SDF-1
 
a
 
, expressed by naive T cells, monocytes, and
dendritic cells, recognized by 12G5, an IgG2a from the NIH
AIDS Repository). Negative controls included an IgG1 hybri-
doma culture supernatant (P3; provided by Dr. M. Hemler, Har-
vard Medical School, Boston, MA) and irrelevant mouse IgG2a
or IgG2b (PharMingen). After exposure to the mAbs, the cells
were stained with FITC-conjugated sheep anti–mouse IgG (Cal-
biochem Corp.) and then analyzed using FACSort™ (Becton
Dickinson). The results are presented as overlaid histograms.
 
Functional Assays.
 
[
 
3
 
H]thymidine was incorporated by 5 
 
3
 
 10
 
4
 
cells in triplicate experiments. The cytokines used in the assays
and their plateau concentrations were SCF (100 ng/ml), IL-6 (50
ng/ml), IL-10 (10 ng/ml), IL-3 (5 ng/ml), IL-2 (5 ng/ml), IL-4
(10 ng/ml), IL-5 (5 ng/ml), G-CSF (5 ng/ml), M-CSF (5 ng/ml),
GM-CSF (5 ng/ml), IL-9 (50 ng/ml), IFN-
 
g
 
 (10 ng/ml), IL-12 (10
ng/ml), or IL-13 (10 ng/ml). Cells were cultured at 37
 
8
 
C and 5% 
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CO
 
2
 
 for 6 d in the presence of the indicated cytokines. The cul-
tures were pulsed for the final 16 h with 1 
 
m
 
Ci/well of [
 
3
 
H]thymi-
dine (NEN Life Science Products; specific activity, 20 Ci/mmol),
harvested with Harvester 96
 
®
 
 MACH II (Tomtec, Inc.), and ana-
lyzed in triplicate with a 1205 Betaplate™ Liquid Scintillation
Counter (Pharmacia). Because the trends for [
 
3
 
H]thymidine incor-
poration were consistent but the absolute values varied consider-
ably among experiments, the results for each cytokine were nor-
malized relative to the incorporation in response to SCF alone in
each experiment, thereby allowing mean 
 
6
 
 SEM to be expressed
for the cumulative data obtained in different experiments.
Changes in the cytosolic free Ca
 
2
 
1
 
 concentration was mea-
sured using Fura-2–loaded hPrMCs and hMCs. The cells were
resuspended in HBSS containing 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
,
and 0.1% BSA and loaded with Fura-2 AM (Molecular Probes,
Inc.) for 30 min at 37
 
8
 
C. After labeling, the cells (5 
 
3
 
 10
 
6
 
) were
washed and resuspended in the above buffer. [Ca
 
2
 
1
 
]
 
i
 
 was mea-
sured using excitation at 340 and 380 nm in a fluorescence spec-
trophotometer (Hitachi F-4500) after stimulation with recombi-
nant chemokines (1–100 nM each), and the relative ratio of
fluorescence emitted at 510 nm was recorded.
The chemotaxis of hPrMC was measured using Transwell
 
®
 
tissue culture inserts with an 8-
 
m
 
m pore size (Corning Costar
Corp.). The cell suspensions (10
 
5
 
) and chemokine dilutions were
made in RPMI 1640 supplemented with 20 mM Hepes, pH 7.5,
and 1% human plasma albumin (Sigma Chemical Co.). Migration
was allowed to proceed for 1 h at 37
 
8
 
C in a 5% CO
 
2
 
–humidified
atmosphere. The membrane was then removed, washed on the
upper side with PBS, fixed, and stained with Diff-Quik
 
®
 
 (Baxter
Corp.). The migrated cells were counted in five randomly se-
lected fields at a magnification of 400. Spontaneous migration
was also determined in the absence of chemokine and subtracted
from chemokine-induced migrated cells. The chemotactic responses
were consistently three- to fourfold greater than the background
cell migration.
 
Reverse Transcriptase PCR.
 
Total RNA was extracted from
cultured cells at 3, 4, 6, and 9 wk using TRI Reagent (Molecular
Research) as previously described (60). Each sample of total RNA
was reverse transcribed after oligo dT priming according to the
manufacturer’s protocol of a commercial reverse transcriptase (RT)
kit (Invitrogen Corp.). The following deoxyoligonucleotide primers
were designed for PCR amplification of human CCR3: sense
strand primer “CCR3A”: 5
 
9
 
-ATG-ACA-ACC-TCA-CTA-GAT-
ACA-GTT-G-3
 
9
 
; and antisense strand primer “CCR3B”: 5
 
9
 
-CTA-
AAA-CAC-AAT-AGA-GAG-TTC-CGG-C-3
 
9
 
. For the amplifi-
cation of CXCR4, the primers were: sense strand primer
“CXCR4A”: 5
 
9
 
-ATG-GAG-GGG-ATC-AGT-ATA-TAC-ACT-
TC-3
 
9
 
; and antisense strand primer “CXCR4B”: 5
 
9
 
-GCT-GGA-
GTG-AAA-ACT-TGA-AGC-TC-3
 
9
 
. The primer locations were
chosen to encompass two exons, thus ensuring that any amplified
genomic contaminant could be distinguished from the transcript
of interest based on size. 10 
 
m
 
l of the reverse transcription reac-
tion mixture was amplified by 35 cycles in an automated thermal
cycler (Perkin-Elmer Cetus Instruments) under the following con-
ditions: 1
 
3
 
 PCR buffer (Boehringer Mannheim) containing 1.5
mM MgCl
 
2
 
, 200 
 
m
 
M dCTP, dTTP, dGTP, and dATP, 10 pmols
of each primer, and 2.5 U of Taq polymerase (Perkin-Elmer
Corp.). The parameters were 94
 
8
 
C for 1 min, 60
 
8
 
C for 1 min,
and 72
 
8
 
C for 1 min. Chain elongation was continued after the
last cycle for 10 min. Duplicate samples of each RT mixture were
also amplified using commercially prepared oligonucleotides for
human glyceraldehyde 3-phosphate dehydrogenase (G3PDH;
Clontech) as an internal standard with the same parameters. The
PCR reaction products were resolved on a 1% agarose gel con-
taining ethidium bromide. The specificity of the resultant appro-
priately sized PCR products was confirmed using an automated
sequencing reaction (Dana-Farber Cancer Institute Molecular Bi-
ology Core Facility, Boston, MA).
 
Results
 
Immunocytochemical and Cytofluorographic Characteristics of
Cultured hPrMCs and hMCs. As defined by metachromatic
staining with toluidine blue dye, no hMCs were identified
among the starting cultures of cord blood mononuclear
cells. During culture in the presence of SCF/IL-6/IL-10,
both the total number of cells and the total number of
toluidine blue–positive cells arising from 3 3 107 cord
blood mononuclear cells increased in all experiments, with
total cells reaching a maximum at week 3 (7.0 6 1.6 3 107
cells) and total toluidine blue–positive cells reaching a peak
at week 5 (3.4 6 0.3 3 107 cells), both declining thereafter
(Fig. 1 A). The decline in total cell number was more rapid
than the decline in toluidine blue–positive cell number. As
a result, the percentage of cells exhibiting toluidine blue
metachromasia progressively increased, reaching .75% of
Figure 1. (A) Total cell numbers (d) and numbers of cells staining
metachromatically with toluidine blue (j) arising over 9 wk from cul-
tures of 3 3 107 cord blood mononuclear cells in the presence of SCF/
IL-6/IL-10. (B) Progressive increase in the percentage of cells with tolui-
dine blue metachromasia. (C) Percentages of cells with tryptase (j) and
chymase immunoreactivity (d) at weeks 4, 6, and 9 of culture. Results
are the means 6 SEM of three experiments.271 Ochi et al.
the cultured cells by week 6 and 100% by week 9 (Fig. 1 B).
The percentages of cells that were positive for tryptase (Fig.
1 C) paralleled the toluidine blue staining and comprised 43 6
2% at week 4, 92 6 2% at week 6, and 100 6 0% at week 9
(mean 6 SEM; n 5 3). Chymase immunoreactivity was evi-
dent in 85 6 3% of the cells at week 4, 100 6 0% at week 6,
and 100 6 0% at week 9 (mean 6 SEM; n 5 3; Fig. 1 C).
In all experiments, the cells had reached homogeneity
for light scatter properties by week 4 (Fig. 2, top row, left),
with monophasic expression of c-kit and CD13 and low-
level monophasic expression of FceRIa (as shown for a
representative experiment, Fig. 2). These 4-wk-old ungated
cells also expressed IL-3Ra monophasically but lacked the
b3 integrin. Neither CD14 nor CD16 was detectable at
week 4 (n 5 3; data not shown). At week 9, the cells also
showed uniform light scatter but of substantially higher in-
tensity (Fig. 2, second row, left). 100% of the ungated 9-wk-
old cells strongly expressed c-kit and CD13, were again
weakly FceRIa-positive, and were IL-3Ra–negative but had
become strongly b3 integrin–positive (Fig. 2). At week 6,
the cells segregated into two populations based on differ-
ences in side angle light scatter (SSC) (Fig. 2, third row,
left); a population of low SSC was indicative of low granu-
larity and a population of high SSC indicated high granu-
larity. Separate cytofluorographic gating revealed that the
low granularity 6-wk-old population (c-kit/CD13/FceRIa/
IL-3Ra–positive, b3 integrin negative) resembled the
4-wk-old population, whereas the high granularity 6-wk-old
population (c-kit/CD13/FceRIa/b3 integrin–positive, IL-
3Ra–negative) resembled the 9-wk-old population in its
distribution of surface epitopes.
Sorting, Characterization, and Culture of Low and High Gran-
ularity Cell Populations at Week 6. To determine whether
the c-kit/CD13/FceRIa/IL-3Ra–positive, b3 integrin–
negative cells of low granularity were progenitors of the
c-kit/CD13/FceRIa/b3 integrin–positive, IL-3Ra–nega-
tive cells of high granularity, the two cell populations were
separated by FACSorting at 6 weeks (Fig. 3 A). Approxi-
mately 20% of the original cells were recovered after the
sorting procedure. 15 6 6% of the low granularity cells
were toluidine blue positive (a representative field shown
in Fig. 3 B), and 11 6 1% were tryptase positive (Fig. 3 C),
whereas 96 6 2% and 94 6 3% stained for chymase and
chloroacetate esterase, respectively (Fig. 3, D and E; n 5 2;
mean 6 half range for all parameters). In contrast, all of the
cells separated into the high granularity group were strongly
positive for toluidine blue (Fig. 3 F), immunoreactive
tryptase (Fig. 3 G), and chymase (Fig. 3 H) and chloroace-
tate esterase activity (Fig. 3 I) (n 5 2).
The respective 6-wk-old separated populations were
maintained for 2 wk of further culture in the presence of
SCF/IL-6/IL-10 and then reanalyzed for their light scatter
characteristics, surface expression of c-kit, CD13, FceRIa,
IL-3Ra, and b3 integrin, and metachromatic staining prop-
erties. The FACSorted 6-wk-old high granularity popula-
tion retained its original level of granularity after the two
additional weeks of culture (Fig. 3 J, right), retained its
original surface distribution of c-kit, CD13, FceRIa, and
b3 integrin, and remained uniformly toluidine blue posi-
tive (not shown). The FACSorted 6-wk-old low granular-
ity population gave rise to two distinct populations on sub-
sequent culture that segregated by differences in granularity
(Fig. 3 J, left). Cytofluorographic analysis revealed that the
population of lower SSC was identical in surface pheno-
type to the original 6-wk-old purified low granularity pop-
ulation (c-kit/CD13/FceRIa/IL-3Ra–positive,  b3 inte-
Figure 2. Cytofluorographic
characteristics of 4- (top row)
and 9-wk-old (second row) cells,
each representing uniform popu-
lations by light scatter (left).
Representative histograms are
shown for c-kit, CD13, FceRIa,
IL-3Ra, and b3 integrin. At
week 6, two cell subpopulations
are indicated by distinct groups
that differ in terms of the height
of SSC. Separate gating and anal-
ysis revealed that the population
of lesser SSC (low granularity;
third row) resembled the 4-wk-
old cells in its surface phenotype,
whereas the higher SSC popula-
tion (high granularity; fourth
row) resembled the 9-wk-old
cells. Expression of each surface
epitope is represented by the
bold tracings, and the isotype-
matched negative controls are
represented by the lighter trac-
ings. Results are representative
of independent experiments per-
formed with cells from three dif-
ferent donors.272 Chemokine Receptors of Mast Cell Progenitors
grin–negative), whereas the newly derived population of
higher SSC was cytofluorographically identical to the orig-
inal sorted high granularity population (c-kit/CD13/FceRIa/
b3–integrin positive, IL-3Ra–negative; not shown). The
evolution of the 6-wk-old sorted low granularity cells into
two populations was accompanied by an increase in the
proportion of cells with toluidine blue positivity (from 15 6
6% to 59 6 3%; n 5 2). Thus, the low granularity popula-
tion, observed uniformly at week 4 and fractionally at week
6, were designated hPrMCs and viewed as providing a pop-
ulation of higher granularity, designated hMCs, observed
initially at week 6 and uniformly at week 9.
Proliferative Responses of hPrMCs and hMCs to Th2 Cyto-
kines and Reinduction of IL-3Ra. Thymidine incorporation
in response to various hematopoietic cytokines was studied
at weeks 4 and 9. At week 4, the cultured cells responded
maximally to SCF among the cytokines tested alone and
also responded to GM-CSF (51 6 11% of the SCF response)
and IL-3 (27 6 3%) alone (n 5 3, as shown for a represen-
tative experiment; Fig. 4 A, left). The 4-wk-old cells did
not respond to M-CSF, G-CSF, IL-2, IL-5, IL-6, IL-9, or
IL-10 alone. No proliferative response was seen to IL-4,
IL-13, IFN-g, or IL-12 (data not shown). Combinations of
SCF with IL-3 (100 6 28%), IL-5 (74 6 18%), IL-6 (43 6
8%), GM-CSF (54 6 26%), and the developmental combi-
nation of IL-6 and IL-10 (58 6 10%) significantly aug-
mented proliferation relative to SCF alone (P , 0.05,
means  6 SEM; n 5 3 for all conditions; Fig. 4 A, center).
Small comitogenic effects were seen for IL-4 (31 6 15%; n 5
2; not shown), and IL-9 (22 6 10%), whereas IL-2, IL-10,
M-CSF, IL-12, G-CSF, and IL-13 (not shown) had no
costimulatory activity. In contrast, IFN-g suppressed the
SCF-driven proliferation of hPrMCs in a dose-dependent
manner (Fig. 4 A, right), with 10 ng/ml IFN-g suppressing
SCF-driven proliferation by 52 6 6% (n 5 2). At week 9,
the cells incorporated thymidine only in response to SCF
among the cytokines tested alone (Fig. 4 B, left). The co-
stimulatory effects of IL-3 (104 6 28%), IL-5 (131 6 22%),
IL-6 (71 6 23%), and GM-CSF (37 6 4%) (Fig. 4 B, cen-
ter; P , 0.05 for each; n 5 3) were retained by these ma-
ture hMCs. IL-9 again had a small comitogenic effect (21 6
5%; mean 6 SEM range; n 5 3). No comitogenic effect
was observed for IL-4 (n 5 3; data not shown). The sup-
pressive effect of IFN-g (71 6 1% at 10 ng/ml) was more
pronounced for hMCs (Fig. 4 B, right) than for hPrMC
(Fig. 4 A, right). None of the comitogenic or suppressive
cytokines elicited a change in the 9-wk-old cell popula-
tions in light scatter or surface epitope distribution, except
for IL-3 and IL-5, both of which caused an induction of
IL-3Ra (Fig. 5), and IL-4, which diminished the signal for
c-kit (not shown). The absolute quantity of SCF-driven
thymidine incorporated was consistently 50–75% lower in
the 9-wk-old cells than in the 4-wk-old cells.
Expression of Chemokine Receptors by hPrMCs and hMCs.
At week 4, CXCR2, CCR3, CXCR4, and CCR5 (n 5 3
each) were expressed in monophasic distributions, with high-
est relative expression of CXCR4 (as shown for a representa-
tive experiment; Fig. 6 A, top). CD4, which acts in concert
Figure 3. FACSorting of 6-wk-old cells into low and high granularity
populations by their light scatter profiles (A). Toluidine blue metachro-
masia (B, F), tryptase immunoreactivity (C, G), chymase immunoreactiv-
ity (D, H), and chloroacetate esterase activity (E, I) are depicted for the
low granularity (left) and high granularity (right) populations. Dot plot
density light scatter profile of cells derived after 2 wk of culture from the
original sorted 6-wk-old populations (J) of low granularity (left) and high
granularity (right). The results are representative of two experiments, and
the fields depict the profile presented quantitatively in the text.273 Ochi et al.
with CCR3, CXCR4, and CCR5 to facilitate HIV entry
into T cells and monocytes, was also expressed at week 4 (Fig.
6 A, top). At week 9, CCR3 was present in a monophasic dis-
tribution (Fig. 6 A, bottom), but CD4, CXCR2, CXCR4,
and CCR5 had reverted to negative (Fig. 6 A, bottom).
CXCR1, CXCR3, CCR1, CCR2, CCR4, CCR5, and
CCR6 were not expressed by hPrMCs or hMCs in any ex-
periment (n 5 2 each; data not shown). RT-PCR revealed
that both CCR3 and CXCR4 mRNA were present at
weeks 3 and 4 and progressively diminished at weeks 6 and
9 (Fig. 6 B). Signals for the internal standard G3PDH were
comparable from lane to lane.
Neither SDF-1a nor ETX (1–100 nM each) were mito-
genic, either alone or in combination with SCF at weeks 4
or 9 (not shown). Both ETX and SDF-1a (1–100 nM)
elicited the rapid intracellular flux of calcium in Fura-2–
loaded hPrMCs studied at week 4. MIP-1a and IL-8 also
elicited dose-dependent calcium flux at a 1–100 nM con-
centration range (data not shown). SDF-1a consistently
elicited a higher and sharper peak of calcium flux than did
ETX (Fig. 7 A), MIP-1a, or IL-8 (data not shown). When
stimulation was performed sequentially with maximally ef-
fective doses of ETX and SDF-1a (100 nM of each), there
was neither potentiation nor inhibition of calcium flux
elicited by the second agonist (not shown). In preliminary
experiments, checkerboard analyses revealed that both
ETX and SDF-1a elicited directional migration and not
chemokinesis. In subsequent transwell migration assays,
ETX and SDF-1a elicited similar dose responses from
hPrMCs and inhibition at high doses, with the net migra-
tion of 26 6 4, 79 6 10, and 55 6 16 hPrMCs per high-
power field in response to 1, 10, and 100 nM ETX, respec-
tively, and 45 6 8, 80 6 9, and 47 6 14 hPrMCs per
high-power field in response to 1, 10, and 100 nM SDF-
1a, respectively (mean 6 SEM; n 5 3 for each agonist;
Fig. 7 A). Neither ETX nor SDF-1a elicited chemotaxis of
9-wk-old hMCs at concentrations as high as 100 nM.
However, ETX provoked a marked and sustained calcium
flux by 9-wk-old hMC (Fig. 7 B). The ETX-induced cal-
cium flux was blocked by prior application of the mAb
Figure 4. Incorporation of [3H]thymidine by 4-wk-old hPrMCs (A) and 9-wk-old hMCs (B) that were cultured for six subsequent days in the pres-
ence of the indicated concentrations of cytokines (ng/ml). Results for individual cytokines (left) are expressed as the means 6 SEM of triplicates and are
representative of experiments performed with the cells of three different donors. The results for comitogenic responses (center) are expressed as the per-
centage increases above the responses to SCF alone and are the means 6 SEM for three independent experiments. IFN-g–mediated suppression of SCF-
driven proliferation of hPrMCs (A, right; means 6 half range, n 5 2) and hMCs (B, right; means 6 SEM, n 5 3) is expressed as the percentage of thy-
midine incorporation occurring in response to 100 ng/ml of SCF alone.274 Chemokine Receptors of Mast Cell Progenitors
7B11 (not shown), indicating that it was mediated entirely
through CCR3. ETX did not elicit histamine release from
either hPrMCs or hMCs (not shown).
Discussion
Among the major effector cells of allergic inflammation,
MCs are unique for their homing to tissues as committed
progenitors and development into mature cells in situ. Be-
cause the circulating levels of PrMCs are small and their di-
rect detection is difficult, little is understood regarding their
homing mechanisms and the regulation of their subsequent
T cell–dependent reactive hyperplasia at sites of allergic mu-
cosal inflammation. We reasoned that these monocyte-like
hPrMCs could be developed in vitro using an SCF-depen-
dent culture system, with IL-6 as a comitogenic cytokine as
Figure 5. Reinduction of IL-
3Ra on fully mature hMCs at
week 9 of culture. hMCs were
transferred to fresh medium con-
taining SCF (100 ng/ml) alone
(top row), SCF plus IL-3 (5 ng/
ml; center row), or SCF plus IL-5
(5 ng/ml; bottom row). Cyto-
fluorographic analysis was per-
formed 1 wk later for the expres-
sion of c-kit (left column), IL-3Ra
(center column), and IL-5Ra
(right column). The results are
representative of the two experi-
ments performed.
Figure 6. (A) Cytofluorographic expression of CXCR2, CCR3,
CXCR4, CCR5, and CD4 by hPrMCs at week 4 (top row) and by hMCs
at week 9 (bottom row). Expression of each surface epitope is represented
by the bold tracings, and isotype-matched negative controls are repre-
sented by the lighter tracings. Results are representative of three experi-
ments with different donor cells (n 5 2 for CXCR2). (B) CCR3 (left) and
CXCR4 (right) mRNA expression determined by RT-PCR analysis at 3,
4, 6, and 9 wk of culture compared with the internal standard, G3PDH.275 Ochi et al.
previously reported for hMCs (36) and with IL-10 added
to suppress monocyte development (43). This approach,
analogous to our prior observations in the mouse (38), per-
mitted the first cytofluorographic characterization of mem-
brane phenotype changes during the SCF-dependent mat-
uration of hPrMCs into hMCs, including their expression
of chemokine receptors, and the study of their comitogenic
responses to Th2 cytokines.
As indicated by flow cytometry, the cultured cord blood–
derived cells were homogeneous in cell size and granular-
ity by week 4, with monophasic low expression of c-kit
and FceRIa and monophasic high expression of CD13 and
IL-3Ra but no expression of the b3 integrin associated
with monocytes and macrophages (53, 54) and dispersed
mature tissue hMCs (52) (Fig. 2). Neither the monocyte
marker CD14 nor the CD16 epitope expressed by neutro-
phils and NK cells was detected on the 4-wk-old cells, pos-
sibly reflecting IL-10–mediated suppression of granulocyte/
monocyte growth (43). The inclusion of IL-10 may also
account for the immunoreactivity for chymase observed in
85% of cells at week 4 (Fig. 1 C), when ,50% were tryptase-
positive or metachromatic (Fig. 1, B and C), as mouse IL-10
induces the expression of two MC chymases in bone mar-
row–derived mouse MCs (61, 62). Progressive increases in
the proportion of mature hMCs occurred with continued
culture, as indicated by increases in metachromasia, tryptase
positivity, and chymase positivity at week 6 (77, 92, and
100%, respectively) and week 9 (virtually 100% for all three
markers), concomitantly with a decline in cell numbers
(Fig. 1 A). The uniformly metachromatic, tryptase- and chy-
mase-positive hMCs comprised a single cell population of
high granularity, as indicated by cytofluorographic SSC at
week 9 (Fig. 2), and expressed high levels of c-kit, CD13,
and b3 integrin and low levels of FceRIa but no detect-
able IL-3Ra. The presence of the b3 integrin and the lack
of IL-3Ra are each consistent with the surface phenotype
reported for hMCs dispersed from skin, uterus, and lung
(52, 55).
The fact that the 6-wk-old cell population clearly segre-
gated into distinct subpopulations (Fig. 2, third and fourth
rows) of low granularity (resembling the 4-wk-old cells in
surface phenotype) and high granularity (resembling the
9-wk-old cells), respectively, provided the opportunity to
demonstrate that the low granularity group contained pro-
genitors of the high granularity group by sorting and subse-
quent culture. Although the sorted low granularity group
at week 6 had lower mean SSC (Fig. 3 A), fewer meta-
chromatic cells (Fig. 3 B), and lower proportions of tryptase-
immunoreactive cells (Fig. 3 C) than the 4-wk-old cells
(Fig. 1) of the same membrane phenotype, they gave rise to
high granularity cells after 2 wk of continued culture with
the same staining and cytofluorographic characteristics as
the 9-wk-old hMCs (Fig. 3 J). As it is possible that the low
granularity population, comprising the majority of cells at
week 4 and a subfraction at week 6, contained both hPrMCs
and another lineage, we used a mitogenic analysis to estab-
lish concordance of the cytokine-mediated responses of
hPrMCs at week 4 and hMCs at week 9.
As determined by incorporation of [3H]thymidine, the
9-wk-old hMCs exhibited mitogenic responses only to SCF
among the cytokines tested alone (Fig. 4 B, left) that was
approximately half of the response observed for the 4-wk-
old hPrMCs. Although the response of the week 4 popula-
tion to IL-3 or GM-CSF alone (27 and 51% of the SCF
response, respectively) could reflect the presence of some
early granulocyte/monocyte or pluripotent progenitor cells
Figure 7. Functionality of CXCR4 and CCR3. Both
ETX (A, top) and SDF-1a (A, bottom) caused transient
dose-dependent calcium flux of Fura-loaded hPrMCs (left
panels) and promoted their directed migration (right pan-
els). At week 9, ETX elicited marked, sustained calcium
flux (B) without chemotaxis (not shown). The calcium
flux assays depicted are representative of three independent analyses at both weeks 4 and 9. The chemotaxis assays were analyzed by counting the num-
bers of migrating cells per five high power fields (HPF) and are the means 6 SEM for three experiments.276 Chemokine Receptors of Mast Cell Progenitors
possibly representing the small chymase-negative fraction
(Fig. 1 C), the absence of a mitogenic response to IL-2, IL-4,
IL-5, IL-6, IL-9, IL-10, IL-13, M-CSF, G-CSF, or IFN-g
alone argues against substantial contamination with hemato-
poietic lineages other than MCs. The synergy observed be-
tween SCF and IL-3 is also recognized for the proliferation
and development of MCs from human peripheral blood
CD34-positive cells (12) and for proliferation of mouse fe-
tal blood promastocytes (11) and mouse metamastocytes
developed in vitro (38) and is therefore consistent with a
response from committed hPrMC. The costimulatory ef-
fect of IL-3 was still observed on the homogeneously ma-
ture 9-wk-old hMCs, even though IL-3Ra was not detected
by cytofluorographic analysis (Fig. 2). However, IL-3Ra was
readily detected after culture of the hMC for 7 d with SCF
plus IL-3 or SCF plus IL-5 (Fig. 5). This is the first cytoflu-
orographic demonstration of IL-3Ra on hMCs and its up-
regulation in response to two important Th2 cytokines.
The comitogenic effect of IL-6 (36, 38) for SCF-driven
MC development has been previously recognized in both
humans and mice, and the comitogenic action of IL-9 was
appreciated in a transgenic mouse model (63) but has not
previously been noted for hMCs. Comitogenic responses
to IL-5 were not previously reported for hMCs but are ap-
parently mediated through low-level surface expression of
a functional IL-5Ra (Fig. 5). This observation is consistent
with the recognition by other investigators that mature
hMCs derived in the presence of SCF and IL-6 express
mRNA for IL-5Ra that encodes a functional protein, as
indicated by IL-5–mediated cytoprotection of hMCs (37).
A critical point in this study is that the same cytokines
elicit comitogenic responses with SCF for hPrMCs at week
4 (Fig. 4 A) and for hMCs at week 9 (Fig. 4 B), compatible
with the retention or reinduction of the required receptors
during MC development and consistent with a role for
each of these cytokines in the amplification of hMC re-
sponses in allergic inflammation. At the same time, the in-
hibition of SCF-driven proliferation of hPrMCs (Fig. 4 A,
right) and hMCs (Fig. 4 B, right) by IFN-g indicates that
this cytokine directly counteracts MC proliferation, simul-
taneously with its polarizing effects on T cells toward a Th1
profile of cytokine production. Finally, the lack of re-
sponses to IL-13 and IL-12 reflects selectivity among the
cytokines within the polarized T cell armamentarium for
their actions on MCs.
Unlike IL-3, IL-5, IL-6, and GM-CSF, IL-4 had rela-
tively small comitogenic effects that were observed only for
hPrMCs. Previous studies have yielded conflicting data on
the role of IL-4 as an MC mitogen. IL-4 suppressed SCF-
driven hMC development in vitro from fetal liver cells (64)
and PBMCs (65) but was comitogenic with SCF for MC
colony formation from mouse committed progenitors (66)
and synergistically induced [3H]thymidine incorporation of
cord blood–derived hMCs when combined with both SCF
and IL-6 (67). The fact that IL-4 potently primes mature
hMCs for FceRI expression (67), IgE-dependent histamine
release (67), and IL-13 production (68) suggests that this
cytokine is a key factor in regulating MC maturation and
function in allergic disease, irrespective of its mitogenic ac-
tions, which vary depending on progenitor cell source and
maturational stage.
Both connective tissue and T cell–dependent mucosal
MC subpopulations arise from a single SCF-dependent lin-
eage as revealed in mice (11, 69). The cytofluorographic
identification of chemokine receptors during development
has not been addressed for MCs in the mouse due to the
lack of reagents. Importantly, those chemokine receptors
noted here could have implications for hPrMC develop-
ment and distribution. CXCR4, CCR3, and CD4 were
expressed in monophasic distributions at week 4 (Fig. 6 A,
top), as were CXCR2 and CCR5, whereas CXCR1,
CXCR3, CCR1, CCR2, CCR4, CCR5, and CCR6 were
absent. At week 9, only CCR3 was still expressed from
among the chemokine receptors, and CD4 was absent (Fig.
6 A, bottom). Although steady-state expression of chemo-
kine receptor mRNA was below the limits of detection by
Northern analysis, RT-PCR confirmed the maturation-
related reductions in CCR3 and CXCR4 mRNA (Fig. 6 B),
indicating the lack of a quantitative relationship between
steady-state mRNA levels and the levels of the correspond-
ing surface proteins. The transition from hPrMC to mature
hMC is therefore accompanied by a change in chemokine
receptor profile, with initial expression of CXCR2, CCR3,
CXCR4, and CCR5, as well as CD4, but retention of
CCR3 only from among these immunodetectable proteins.
The CXCR2/CCR3/CXCR4/CCR5-positive profile of
chemokine receptor expression for hPrMCs is unique
among hematopoietic cells (58) and may explain the distri-
bution of MCs under basal conditions as well as their re-
cruitment to diverse sites of inflammation. The retention of
only CCR3 by hMCs may reflect the importance of CCR3
and its ligands (ETX, MCP 2-4, RANTES) in allergic in-
flammation. Furthermore, the expression of all three HIV
coreceptors (56, 57) and CD4 by hPrMCs suggests that these
cells could carry HIV into tissues.
Both ETX and SDF-1a induced rapid, transient concen-
tration–dependent calcium fluxes and chemotactic responses
of 4-wk-old hPrMCs (Fig. 7), as did MIP-1a and IL-8 (not
shown). SDF-1a consistently induced a sharper and higher
increase in intracellular calcium than did ETX in 4-wk-old
hPrMCs (Fig. 7 A, bottom and top, respectively), but the
two chemokines elicited nearly equal migration, with su-
perimposable dose–response curves at 1–100 nM (Fig. 7 A).
Although ETX did not elicit chemotaxis of 9-wk-old
hMCs, it did cause a marked, sustained dose-dependent
calcium flux (Fig. 7 B). Whereas chemokines typically elicit
transient calcium fluxes that are required for chemotactic
responses, sustained calcium fluxes are associated with cell
differentiation and translocation of NF-AT (nuclear factor of
activated T lymphocytes) transcription factors (70). The
observations imply that ETX may have functions for sta-
tionary hMCs within tissues that are distinct from its ac-
tions on blood-borne hPrMCs.
The findings of this study, analogous to eosinophil traf-
ficking in allergic inflammation, favor a model of cognate
functions for chemokines and Th2 cytokines in regulating277 Ochi et al.
the levels of tissue MCs in allergic diseases. The transit of
hPrMCs from the circulation to various sites within the tis-
sues may be regulated by their expression of CXCR2,
CCR3, CXCR4, and CCR5 and the local availability of
the corresponding respective ligands. SDF-1a, for exam-
ple, is constitutively expressed by stromal cells in various
tissues (which are also a source of the required MC growth
factor SCF), and participates via CXCR4 in basal traffick-
ing of naive T cells (40, 71). Lung expression of the CCR5
ligand MIP-1a is rapidly upregulated in response to inhaled
allergen challenge and is linked to the mobilization of
leukocytes to the bronchial tissue in the first few hours af-
ter challenge (72). Furthermore, MIP-1a and MIP-1b are
implicated in the recruitment of MCs to regional lymph
nodes in response to experimentally elicited cutaneous
contact hypersensitivity in mice (73). The expression of
CXCR2, which was previously localized to the granules
of skin hMCs and to the surface of the primitive MC line,
HMC-1 (59), may permit IL-8–induced recruitment of
hPrMCs; indeed, elevated levels of IL-8 are reported in
both the sera and lung tissue of asthmatics and correlate with
disease severity (74). The expression of CCR3 throughout
hMC development, accompanied by the losses of CXCR2,
CXCR4, and CCR5, is compatible with the proposed crit-
ical role for ETX in allergic inflammation. ETX, expressed
by epithelial cells (29), may provide an important stimulus
for hPrMC movement toward mucosal surfaces. Further-
more, the loss of chemokine receptor expression or ligand-
initiated migration may be a mechanism for tissue retention
of MCs. IL-3, IL-5, and GM-CSF are locally available
within and near the epithelial surface in asthma patients
(75), and each may augment local SCF-dependent prolif-
eration of hPrMCs and mature hMCs in addition to their
cytoprotective functions. The IL-9 gene is implicated as a
candidate gene for asthma in humans (22) and for bronchial
hyperresponsiveness in mice (76) based on linkage studies
and causes a marked hyperplasia of intraepithelial MCs
accompanied by methacholine hyperresponsiveness when
overexpressed in the bronchial epithelia of mice (77). Thus,
Th2 cytokine–driven cytoprotection, proliferation, and
migration of hPrMCs and hMCs may account for mucosal
MC hyperplasia; and the shared responses of MCs, eosino-
phils, and basophils to Th2-derived cytokines are part of
the integrated profile of allergic/asthmatic inflammation in
which this mucosal MC hyperplasia is observed. Con-
versely, the lack of intraepithelial intestinal MCs in humans
with T cell immunodeficiencies (16) and the lack of mu-
cosal MC hyperplastic responses in T cell–deficient mice
(15) likely reflect deficiencies in several local cytokines and
perhaps an additional lack of T cell–dependent ETX pro-
duction by local epithelial cells (31).
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